[ad_1]
TORONTO, March 9, 2022 /PRNewswire-PRWeb/ — In clinical trials of new drugs that have direct or indirect effects on the central nervous system (CNS), regulatory and medical/scientific groups must be confident that application of the drug at its established clinical dose is not associated with negative effects on brain function. Cognition is one important marker of CNS function. In late phase clinical trials, the nature and magnitude of changes in cognition can provide an accurate index of negative CNS effects of the new drugs being studied.
While information about the effects on cognition are used commonly to guide drug development in early phase studies, in late phase clinical trials the design and execution of cognitive tests, and the analyses of the data …
Full story available on Benzinga.com
[ad_2]
Source link
